Abstract:Non-small-cell lung cancer (NSCLC) ranks as a leading cause of cancer-related death globally. Brain metastases are a frequent complication of NSCLC, with 25-40% of patients developing brain metastases during the course of the disease, often within the first 2 years after diagnosis of the primary tumor. Improvements in neurological symptoms and performance status have been reported with whole-brain radiation therapy (WBRT) in combination with steroid therapy in NSCLC patients. In addition, a survival benefit has been reported for patients with a single brain metastasis treated with stereotactic radiosurgery, while the clinical outcome is improved with surgery followed by WBRT versus WBRT alone. However, due to their poor performance status, many patients with brain metastases are not eligible for surgery or radiosurgery. Furthermore, the role of systemic chemotherapy for the treatment of brain metastases is controversial due to the impenetrable nature of the blood brain barrier (BBB), with reported response rates to chemotherapy ranging from 15-30% (overall survival [OS] 6-8 months). Response rates of brain metastases to EGFR tyrosine kinase inhibitor (TKI) treatment (e.g. gefitinib, erlotinib, afatinib) in patients with NSCLC harboring EGFR mutations reach 60-80%, with a complete response rate as high as 40%. Median OS is 15-20 months, and progression-free survival in the brain reaches 6.6-11.7 months, demonstrating an improved clinical outcome. Metastatic involvement of the CNS appears to be a relatively common complication in patients with ALK-positive NSCLC and the CNS represents a dominant site of progression in ALK-positive patients treated with the ALK TKI crizotinib. In addition, CNS progression on crizotinib contributes substantially to the high levels of morbidity and mortality observed among patients with ALK-rearrangements, a finding that is consistent with low CNS penetration of the drug. Second-generation ALK inhibitors (ceritinib, alectinib) are well-tolerated and demonstrate excellent intracranial activity. The various reports of dramatic and prolonged responses in brain metastases patients treated with EGFR and ALK TKIs suggest that these agents may be a valid treatment option for patients with asymptomatic brain metastases from NSCLC, especially for those with EGFR-activating mutations or harboring ALK rearrangement. However, larger phase III studies are required to fully define the activity of these agents and their place in the therapeutic armamentarium of brain metastases.

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Treated Epidermal Growth Factor Receptor-Mutant Non-Small-cell Lung Cancer from the Perspective of Long-Term Radiation Brain Damage: A Multi-Institutional Retrospective Analysis.

Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Treatment of Brain Metastasis from Non-Small Cell Lung Cancer

Radt-28. The Role Of Cranial Re-Irradiation In Egfr Mutant Lung Cancer Patients With Brain Metastases

Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non–small cell lung cancer patients with brain metastases

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.

Impact of Different Timing of Radiation Therapy in Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer.

Early Radiation Therapy Combined with Egfr-Tki is Associated with Longer Survival in Egfr-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases

The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience

Surgery of enlarging lesions after stereotactic radiosurgery for brain metastases in patients with non‐small cell lung cancer with oncogenic driver mutations frequently reveals radiation necrosis: case series and review

Timing of Brain Radiation Therapy Impacts Outcomes in Patients with Non-small Cell Lung Cancer Who Develop Brain Metastases

Epidermal growth factor receptor mutations: association with favorable local tumor control following Gamma Knife radiosurgery in patients with non–small cell lung cancer and brain metastases

Optimal Timing of Hypofractionated Stereotactic Radiotherapy for Epidermal Growth Factor Receptor-Mutated Non-Small-cell Lung Cancer Patients with Brain Metastases.

Brain Metastases in NSCLC - Are TKIs Changing the Treatment Strategy?

Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique

Tyrosine Kinase Inhibitors With and Without Up-Front Stereotactic Radiosurgery for Brain Metastases From EGFR and ALK Oncogene–Driven Non–Small Cell Lung Cancer (TURBO-NSCLC)

Radiotherapy for Asymptomatic Brain Metastasis in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Without Prior Tyrosine Kinase Inhibitors Treatment: a Retrospective Clinical Study

Cyberknife Radiosurgery on the Brainstem Metastases of Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC) and Central Nervous System (CNS) Metastases: Role of Tyrosine Kinase Inhibitors (tkis) and Evidence in Favor or Against Their Use with Concurrent Cranial Radiotherapy.